newsfilter
← Latest News
GlobeNewswire·

Eliem Therapeutics Reports Second Quarter Financial Results

On track to advance two clinical programs through five proof-of-concept trials and progress two preclinical programs over the next 18-24 months Recently completed an IPO for $92 million in gross proceeds that, along with existing cash, provides cash r